ENO2 and non-small cell lung carcinoma: Ferrigno et al. [14] enrolled 448 NSCLC patients (stage I–IV), assessed NSE before treatment and found that patients with NSE > 11 ng/ml had a worse prognosis than patients with lower NSE levels.